Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients

Till Adhikary 1, Annika Wortmann 1, Florian Finkernagel 1, Sonja Lieber 1, Andrea Nist 2, Thorsten Stiewe 2, Uwe Wagner 3, Sabine Müller-Brüsselbach 1, Silke Reinartz 3 and Rolf Müller 1*

Abstract

Background: Although tumor-associated macrophages (TAMs) are essential for cancer progression, connections between different clinical outcomes and transcriptional networks have not been reported. We have addressed this issue by analyzing global expression patterns of TAMs isolated from the ascites of ovarian cancer patients.

Results: TAMs isolated from different ovarian cancer patients can be stratified by coexpression or principal component analysis into subgroups with specific biological features and associated with distinct clinical outcomes. A hallmark of subgroup A is a high expression of clinically unfavorable markers, including (i) high CD163 expression, a surface receptor characteristic of an anti-inflammatory activation state, (ii) increased PCOLCE2 expression, indicative of enhanced extracellular matrix organization, and (iii) elevated ascites levels of IL-6 and IL-10, linked to the aggressiveness of ovarian cancer and immune suppression. In contrast, subgroup B TAMs are characterized by the upregulation of genes linked to immune defense mechanisms and interferon (IFN) signaling. Intriguingly, analysis of published data for 1763 ovarian cancer patients revealed a strong association of this transcriptional signature with a longer overall survival. Consistent with these results, IFNγ was able to abrogate the suppressive effect of ovarian cancer ascites on the inducibility of IL12B expression and IL-12 secretion, a key determinant of a cytotoxic immune response.

Conclusions: The survival of ovarian cancer patients is linked to the presence of TAMs with a transcriptional signature that is characterized by a low expression of protumorigenic and immunosuppressive markers and an upregulation of genes linked to interferon signaling. The observed IFNγ-mediated restoration of the inducibility of IL-12 in the presence of ascites provides a possible explanation for the association of an interferon signaling-associated signature with a favorable clinical outcome.

Keywords: Ovarian cancer ascites, Tumor-associated macrophages, Interferon signaling, CD163, Interleukin 6, Interleukin 10, PCOLCE2

* Correspondence: rmueller@imt.uni-marburg.de
1 Institute of Molecular Biology and Tumor Research (IMT), Center for Tumor Biology and Immunology (ZTI), Philipps University, Marburg, Germany
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Ovarian tumors ranks fifth as the cause of cancer-related death in women and represents the deadliest of all gynecological tumors [1, 2]. More than 90% of ovarian cancers are carcinomas that originate from the ovarian surface or fallopian tube epithelium. High grade serous adenocarcinoma is the most common ovarian carcinoma subtype, with most patients presenting with advanced stage disease and disseminated tumor masses at the time of diagnosis. Although most ovarian cancers are highly sensitive to first-line adjuvant chemotherapy, the disease has a dire prognosis with an overall 5-year survival rate of less than 40% [1, 2]. Several characteristic features contribute to the fatal nature of high grade serous ovarian adenocarcinoma, including the shedding of tumor cells at a very early stage of the disease, their spreading via the peritoneal fluid to form transcoelomic metastases and the tumor-promoting and immune suppressive effect of the peritoneal tumor environment, frequently formed by the malignancy-associated effusion within the peritoneal cavity, commonly referred to as malignant ascites. This tumor microenvironment, consisting to a large extent of host-derived cells, is crucial for the growth, progression, therapy resistance and immune escape of malignant tumors, including ovarian cancer [3].

The most common cell types in ovarian HGSC-associated ascites are macrophages and T lymphocytes [3]. Tumor-associated macrophages (TAMs) can be derived from both blood monocytes [4–6] or resident tissue macrophages [7–13], with the latter most likely representing the major origin of TAMs in ovarian cancer [14]. TAM activation is skewed by factors of the tumor microenvironment to adopt a spectrum of phenotypes that represent mixed forms of alternatively activated (immune regulatory) and pro-inflammatory macrophages [15], which has also been clearly demonstrated for TAMs in ovarian cancer ascites [16]. TAMs do not possess tumoricidal activity, but are rather thought to promote immune suppression and various aspects of cancer growth and progression, including tumor cell invasion, angiogenesis and metastasis [15]. Consistent with these tumor-promoting functions of TAMs, expression of the alternative activation marker CD163 in TAMs has been previously published [16]. TAMs were analyzed by flow cytometry for surface expression of CD14, CD16, CD32, CD64, CD163 and CD206 as described [16]. Tumor cell spheroids and T cells were analyzed as previously published [21].

Methods

Patient samples

Ascites was collected from patients undergoing primary surgery at the University Hospital in Marburg. Patient characteristics are presented in Additional file 1: Table S1.

Isolation and immunophenotyping of cells from ovarian cancer ascites

Mononuclear cells were isolated from ascites by Lymphocyte Separation Medium 1077 (PromoCell) density gradient centrifugation and further purified by magnetic cell sorting (MACS) using CD14 microbeads (Miltenyi Biotech) [16]. TAMs were analyzed by flow cytometry for surface expression of CD14, CD16, CD32, CD64, CD163 and CD206 as described [16]. Tumor cell spheroids and T cells were analyzed as previously published [21].

Isolation and culture of monocyte-derived macrophages

Monocyte-derived macrophages (MDMs) were generated from monocytes (6-day differentiation period) from healthy donors as described [22] and cultured in RPMI medium with 5% human male AB serum (Sigma-Aldrich, Taufkirchen, Germany) or cell-free ascites from ovarian cancer patients, as indicated. T cell from peripheral blood were isolated as described for ascites [21]. Buffy coats were obtained from the blood bank at UKGM Giessen, Germany.

RT-qPCR

Isolation of RNA and RT-qPCR were carried out as described [23]. The following primers were used:

- RPL27_fw: 5′ AAAGCTGTCATCGTGAAGAAC
- RPL27.rev: 5′ GCTGTCACTTTGCGGGGTTAG
- IL12B_fw: 5′ GCGAGGTTCTAAGCCATTCG
- IL12B.rev: 5′ AAGCAGTTAGCAAGGAAGGTC
- CXCL10_fw: 5′ AAGCAGTTAGCAAGGAAGGTC
CXCL10_rv: 5’ GACATATACTCCATGTAGGGAA GTGA
GBP4_fw: 5’ TCTAAAAGGCATTAGAGATTCTTGA
GBP4_rv: 5’ GTGGAGCCCGCAGGGAGAAG
GPNMB_fw: 5’ CTATGAGAGAAGACTCGAAATG
GPNMB_rv: 5’ GTTATGATGGCTTTGGCCGG
LGALS2_fw: 5’ CCACGATGTCGCCCCTGAG
LGALS2_rv: 5’ CGGCTTCAATGTCATATGTC
KITLG_fw: 5’ GCCAAGCTCTTACAGGCAG
KITLG_rv: 5’ GAAACTCTCCTCCTCTTCTTG
MRC1_fw: 5’ CCT CCG ACC TGG TTA GGG
MRC1_rv: 5’ GGATGTGTGGTCTCCTCTGG

ELISA
Concentrations of p40 (IL-12B/IL-23) in cell culture supernatants were determined using an ELISA Kit from BioLegend/Biozol (Eching, Germany) according to the instructions of the manufacturer. IFNγ, IL-6 and IL-10 levels in ascites were quantified by ELISA kits purchased from eBioscience (Frankfurt, Germany).

RNA sequencing (RNA-Seq)
RNA isolation and RNA-Seq was carried out on an Illumina HiSeq 1500 as described [21]. Genome assembly and gene model data were retrieved from Ensembl release 81. Sequencing data were deposited at EBI ArrayExpress (accession numbers E-MTAB-5199 and E-MTAB-4162).

Statistical analysis of experimental data
Paired and unpaired t tests were carried out with the Python functions scipy.stats.ttest_rel() and scipy.stats.ttest_ind(), respectively. Results were expressed as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Confidence intervals were calculated using the bootstrap method. Further statistical analyses were performed using the Python functions numpy.percentile() and pandas.DataFrame.boxplot().

Analysis of RNA-Seq data
RNA-Seq data was aligned to Ensembl v81 using STAR (version 2.3.1z13_r470) and processed as reported [21]. The number of mapped reads was in the range of 19.74–35.92 million (median 29.42 million). TPM (transcripts per million) values were calculated based on the total gene read counts and length of merged exons and corrected for contamination by tumor cells as described [21]. The source code for implementing the algorithm for TPM correction has also been deposited at GitHub (https://github.com/IMTMarburg/rnaseqmixture). Genes were considered expressed if they had a minimum TPM value of 3. TAM samples with TPM >50 for EPCAM or MSLN were excluded due to presumed tumor cell contamination. All genomic sequence and gene annotation data were retrieved from Ensembl release 81, genome assembly hg38.

PCA and delineation of differentially expressed gene clusters
PCA was carried out on using the sklearnPCA(n_components = 2, whiten = True) and sklearn_pca.fit_transform() functions (Python) on RNA-Seq data. Pearson correlation coefficients (r) were determined with scipy.stats.pearsonr(). The Bioconductor package edgeR [24] was used for the delineation of high variance gene clusters differentially regulated in subgroups of TAMs identified by PCA (signatures 1 and 2).

Coexpression analysis
Genes with the greatest expression variance were identified by pandas.DataFrame.var(). Pearson correlation coefficients (r) were determined for the 3000 top genes using scipy.stats.pearsonr(). Sets of genes with r > 0.89 and n > 10 were combined (n = 629) and analyzed by hierarchical clustering using the scipy.cluster.hierarchy functions linkage (method = “weighted”, metric = “correlation”) and dendrogram (truncate_mode = “none”, color_threshold = 0.8). The resulting 4 clusters (I, II, III, IV) were analyzed for intersections the signatures identified by PCA (see above), which revealed close relationships of cluster I with signature B and cluster III with signature A.

Pathway analyses
Gene sets were analyzed for Upstream Regulators using the Ingenuity Pathway Analysis (IPA) database (Qiagen Redwood City, CA, USA) as described [22]. Functional annotations were performed by gene ontology (GO) enrichment analysis (http://geneontology.org).

Survival analyses
Overall survival (OS) data were retrieved from PRECOG (http://pre cog.stanford.edu) [25]. Associations between gene expression and relapse-free survival (RFS) were analyzed by the web-based tool “KM Plotter” [26] (http://kmplot.com) using the following settings: ‘auto select best cutoff’, probe set option: ‘JetSet best probe’, histology: serous, datasets: all; other settings: default.

Results
Clustering of ovarian carcinoma TAM samples
The transcriptomes determined for 18 independent samples of TAM isolated from the ascites of ovarian cancer patients (Additional file 2: Dataset S1) were analyzed for potential similarity patterns by different approaches, as schematically summarized in Fig. 1. These samples were selected for very low contamination with tumor cells, as indicated by low TPM values (<50) for the epithelial
marker genes EPCAM and MSLN. Furthermore, we excluded all genes (n = 13) highly expressed in tumor cells or T cells versus TAMs (>100-fold) to minimize interference by contaminating cells.

Genewise normalized TAM transcriptomes were used for the bioinformatic delineation of similarity patterns. Principal component analysis (PCA) did not yield a clear partitioning of TAM samples into subgroups, although eigenvalues suggested that the first two components can explain most of the data. We therefore additionally grouped samples according to the expression of CD163, previously established as a TAM marker associated with a poor clinical outcome of ovarian cancer [16]. Combining PCA with the expression pattern of this surrogate marker revealed two discernible subgroups (A and B; Fig. 2a), which was confirmed by Pearson correlation (Fig. 2b) and distance-based multidimensional scaling analysis (Additional file 3: Figure S1). Two other markers associated with pro-tumorigenic functions, i.e., IL6 (interleukin 6) [14, 16–21, 27] and PCOLCE2 (pro-collagen C-endopeptidase enhancer 2; see Additional file 3: Figure S2), showed a similar pattern of expression, except for IL6 expression in TAM117 (Fig. 2c-e), which was confirmed by flow cytometry (Fig. 2f) and distance-based multidimensional scaling analysis (Additional file 3: Figure S1). Two other markers associated with pro-tumorigenic functions, i.e., IL6 (interleukin 6) [14, 16–21, 27] and PCOLCE2 (pro-collagen C-endopeptidase enhancer 2; see Additional file 3: Figure S2), showed a very similar pattern of expression, except for IL6 expression in TAM117 (Fig. 2c-e). Based on this data we defined subgroup A as TAM90, TAM91, TAM101, TAM103, TAM104 and TAM105 expressing CD163, PCOLCE2 and IL6 at high levels relative to the subgroup B samples TAM80, TAM82, TAM112, TAM114, TAM116 and TAM118. These subgroups were confirmed by flow cytometry showing a significantly higher fraction of CD163⁺ and CD163⁺CD206⁺ cells in subgroup A versus subgroup B TAMs, which was not observed for other macrophage markers (Fig. 2f).

Taken together, these data indicate that cluster A TAMs are skewed towards alternative activation (CD163), extracellular matrix (ECM) remodeling (PCOLCE2) and promotion of tumor growth (IL-6). As these markers are associated with a short relapse-free survival, it is likely that cluster B is linked to a favorable clinical outcome. This conclusion is supported by the observation that the ascites concentrations of IL-10, highly predictive of a poor survival of ovarian cancer [21, 28] was consistently and dramatically increased in subgroup A versus subgroup B patients (Fig. 2g). A similar pattern was observed with IL-6 (with one outlier; Fig. 2g), also associated with a short time to relapse [17, 18, 21].

**Cluster-specific gene expression**

To gain more insight into the specific phenotypes of subgroup A and B TAMs, we analyzed the RNA-Seq data sets with edgeR, a Bioconductor package for reliable gene-specific dispersion estimation in small datasets [24]. The edgeR tool identified a group of 932 genes differentially expressed in the two subgroups of TAMs with an FDR of <0.05 (Additional file 1: Table S1; Fig. 3a; Additional file 2: Dataset S2). Of these, 329 genes were upregulated in subgroup A versus B, and 603 genes showed the opposite pattern (Fig. 3a; Additional file 2: Datasets S3 and S4). These gene sets were termed signature A and signature B. In contrast to these protein coding RNAs, edgeR did not identify any differentially expressed
IncRNAs (FDR <0.05) in our RNA-Seq data set (annotated IncRNAs: n = 7527).

Gene ontology (GO) enrichment analysis identified significant associations of signature A with diverse biological processes, including ECM remodeling, locomotion, endocytosis as well as lipid and carbohydrate catabolism (Fig. 3b). In contrast, innate immune defense mechanisms, T cell activation and IFN signaling were strongly associated with signature B (Fig. 3b). Consistent with these findings, Ingenuity Upstream Regulator Analysis indicated that signature B genes are major targets of proinflammatory pathways triggered by lipopolysaccharide (LPS), tumor necrosis factor α (TNF) and INFγ (Fig. 3c), with all three target gene sets showing strong overlaps (Additional file 3: Figure S3).

The differential expression patterns of signature A and B genes are shown in Fig. 3d and Additional file 3: Figure S4 for the IFN and ECM gene sets identified by GO enrichment analysis as representative examples. As expected, these gene sets showed opposite patterns of regulation and the subgroup-selective expression was clearly significant for the vast majority of genes (n = 48 out of n = 51). The RNA-Seq data for several genes identified by edgeR were confirmed by RT-qPCR (Fig. 3e).

Taken together, these observations point to a relatively high complexity of biological functions affected by signature A genes, while the role of signature B genes appears to be specifically associated with IFN-stimulated immune defense mechanisms.

Confirmation of clustering by coexpression analysis

To obtain independent evidence for the robustness of the clusters defined by PCA and edgeR we performed coexpression analysis the genes showing the highest variance across all TAM samples. Pearson correlation and hierarchical clustering yielded three large clusters of coregulated genes (Fig. 4a; Additional file 3: Figure S5;
Additional file 2: Datasets S5-S7). Hierarchical clustering of TAM samples using a combined set of these genes (Fig. 4a) yielded the identical partitioning into subgroups A and B as the PCA-based approach in Fig. 2a. Consistent with this observation, two of these gene clusters showed substantial and specific overlaps with signatures A and B, respectively, i.e., cluster I with signature A (120/140 = 85.7% and no overlap with signature B); cluster III with signature B (148/266 = 55.6% and no overlap with signature A), as shown in Fig. 4c as well as Additional file 2: Datasets S8 and S9.

Functional annotations revealed endocytosis and chemotaxis for cluster I, chromatin modification and splicing for cluster II, and immune defense and interferon signaling for cluster III (Fig. 4d). Consistent with the overlaps of described in the preceding paragraph, the GO terms for cluster I were also found for signature B, and the terms for cluster III correspond to those for signature A (compare Figs. 3b and 4d).

Finally, expression of cluster I genes was higher in subgroup B versus subgroup A (Fig. 4e), and vice versa, expression of cluster III genes was higher in subgroup A relative to subgroup B (with the exception of TAM101 (Fig. 4g). In contrast, no differential expression was observed for cluster II genes (Fig. 4f). Taken together, these findings clearly suggest that cluster III corresponds to signature A, while cluster I corresponds to signature B. Thus, both strategies, PCA of patient samples followed
by edgeR and coexpression analysis of high variance
genes yielded very similar results, and identified IFN sig-
naling as a hallmark of signature B upregulated in sub-
type B TAMs.

Association of signature B, interferon signaling
and survival
In order to identify potential associations between the
expression of this genes in ovarian cancer with clinical
outcome we made use of the PRECOG database, which
contains the results of a meta-analysis of 1763 patients
from 12 studies [25]. These studies used solid ovarian
tumor tissue containing substantial amounts of myeloid
cells [25, 29] for transcriptome analysis, suggesting that
the PRECOG data are also suitable for testing survival
associations for genes expressed in abundant tumor-
associated host cells, such as TAMs.

Signature A, cluster III and their overlap comprised
similar fractions of genes associated with poor or favorable
OS (Fig. 5a and top panel in Additional file 3: Figure S6).
Only when genes with distinct functional annotations
were analyzed separately a clear OS association was
detectable. Thus, signature A genes linked to ECM re-
modeling were strongly associated with a short OS
(Fig. 5a and Additional file 3: Figure S7). In contrast,
signature B, cluster I and their overlap were clearly
linked to a favorable clinical outcome (Fig. 5a and bottom
panel in Additional file 3: Figure S6). This applied in
particular to the IFN signaling-associated genes of sig-
nature B, as shown in detail in Fig. 5b. A similar inverse
association with relapse-free survival was also found
based on data from the KM plotter database, as exem-
plified for IRF1 and TAP1 in Fig. 5c and d. All PRECOG
z-scores for signature A and B genes are also listed in
Additional file 2: Dataset S10.

These associations with a favorable clinical course are
not simply consequence of the extent of myeloid cell
infiltration. First, activation state-independent myeloid
marker genes, such as CD14 or CD68 did not show any significant association with ovarian cancer OS (PRECOG) [25] or RFS [26] (Fig. 5e and f). Second, tumor infiltration by myeloid cells inferred from RNA expression data (CIBERSORT) [29] showed no significant association with OS, with a trend towards a worse clinical outcome for monocytes (Additional file 3: Figure S8). Third, a number of the IFN signaling-associated genes of signature B are expressed at high levels (TPM > 10) selectively in TAMs compared to tumor cells or tumor-associated CD3

Fig. 5 Association of cluster-specific gene expression with ovarian cancer survival. a Mean z-scores (OS) for signature A and B genes; the ECM-related and IFN signaling-associated genes of signature A and B, respectively; cluster III and I genes; and genes representing the intersection of signature A with cluster III or of signature B with cluster I. Survival data were obtained from the PRECOG database with 1763 ovarian cancer patients [25]. b OS z-scores for signature B genes that are associated with IFN signaling. Significant associations with a favorable clinical outcome are shown in blue (z-score < −2.0; HR <1). The corresponding data for the complete signatures A and B are shown in Additional file 3: Figure S6. c-f Kaplan-Meier plots analyzing the association of IRF1, TAP1, CD14 and CD68 with RFS of high-grade serous ovarian cancer determined by KM plotter [26]. g Expression of the signature B genes HLA-DPB1, HLA-DRA and KYNU in TAMs (blue, n = 33), tumor cells (red, n = 15) and CD3+ TATs (green, n = 5) isolated from ovarian cancer ascites
lymphocytes (TATs) isolated from ovarian cancer ascites, as exemplified by HLA-DRA, HLA-DPB1 and KYNU in Fig. 5g).

Expression of IFN-encoding genes is linked to ovarian cancer survival

Analysis of the PRECOG database also revealed a significant association of IFNG expression with a longer survival (z < −2; Fig. 6a). Similar associations were also found for several genes coding for type I IFNs, i.e., IFNA1, IFNA2, IFNA14 and IFNB1. Evaluation of RNA-Seq data for different cell types [21] (Additional file 2: Dataset S1) showed that tumor-associated T cells (TATs) express IFNG at relatively high levels (TPM = 10–100), while TAMs and tumor cells do not (Fig. 6b). Interestingly, all TAT samples expressed IFNG at higher levels than normal CD3+ T cells isolated from the blood of healthy donors, with >10-fold higher levels observed with three out of the five patients analyzed. It is therefore likely, that partially activated TATs are a major source of IFNγ within the tumor microenvironment and the malignancy-associated ascites. This is consistent with the presence of readily detectable IFNγ levels in the ascites of a subgroup of patients (n = 21 above ELISA detection limit out of a total of n = 61 samples; Fig. 6c). By contrast, all type I IFN genes associated with a favorable OS were expressed a very low levels by all three cell types, if at all (Additional file 3: Figure S9).

IFNγ prevents the ascites-induced IL12B activation block in macrophages

Interleukin-12 (IL-12) is a particularly interesting cytokine in the context of ovarian cancer due to its immune stimulatory anti-tumor effects and its inverse associations with disease progression patients [30–32]. A hallmark of TAMs in ovarian cancer ascites is their defect to release IL-12 in response to inflammatory stimuli, which results from a transcriptional block of the IL12B gene.
gene encoding the p40 subunit [14, 33, 34]. Another cytokine with beneficial immune stimulatory and anti-tumor effects in ovarian cancer patients is IFNγ [35–38], consistent with the observation that IFNγ can prevent the skewing of monocyte differentiation by ovarian cancer ascites from immunostimulatory IL-10lowIL-12high macrophages to TAM-like IL-10highIL-12low cells [34]. To assess the relevance of the IFN signaling-associated signature B we explored the relationship between IL-12 and IFNγ in further detail.

Toward this end, we measured the inducibility of *IL12B* mRNA by lipopolysaccharide (LPS) plus IFNγ in monocyte-derived macrophages that were differentiated either in the presence of regular cell culture medium (R5) or in ascites, both in the absence or presence of IFNγ during macrophage differentiation. As expected, all ascites samples tested blocked *IL12B* induction, which, however, was almost completely prevented by IFNγ (Fig. 6d). In full agreement with these findings, secretion of p40 was strongly induced by LPS plus FNγ in R5, which was blocked by ascites only in the absence of IFNγ during differentiation (Fig. 6e). These results clearly point to a clinically beneficial IFNγ – p40/IL12B axis in differentiating myeloid cells in the ovarian cancer microenvironment, thus providing a potential explanation for the association of subgroup B TAMs with clinically favorable parameters.

**Discussion**

**Delineation of subgroups of TAMs**

Transcriptional signatures of TAMs distinguishing subgroups of patients in a biologically or clinically meaningful way have not been reported to date. We have used the ovarian cancer-associated ascites as an experimental system to address this issue by an unbiased approach (Fig. 1). By applying PCA to data derived by next generation sequencing we were able to split TAM samples from different patients into subgroups characterized by distinct gene expression patterns (Fig. 2). Remarkably, cluster B is basically congruent with the subgroup of patients with low expression of the *IL6, PCOLCE2* and *CD163* genes, a low fraction of anti-inflammatory CD163+/CD206+ TAMs and low ascites concentrations of IL-10 and IL-6 (Fig. 2c-g). These features are known as negative prognostic factors for different tumor entities, including ovarian cancer [16–18, 21, 28, 39, 40]. The same subgroups were also identified by an another unbiased approach, i.e., coexpression analysis of all TAM samples (Fig. 4). Therefore, these findings clearly suggest that subgroups A and B represent patients with a poor and favorable clinical outcome, respectively.

**IFN signaling is a hallmark of signature B TAMs**

Intriguingly, a hallmark of subgroup B is the upregulation of target genes of the IFN signaling network (Figs. 3b and 4d). Consistent with this finding, our analysis of the PRECOG database revealed a strong association of these genes with a longer OS (Fig. 5b). This is in agreement with previous studies which associated a high protein expression of several IFN signaling components with a favorable clinical outcome, including IRF1 [41]. Furthermore, IFNγ inclusion in the first-line therapy of ovarian cancer resulted in an effector immune cell response [35] and a prolongation of progression-free survival [36, 37], while type I IFNs had no benefit [42]. In keeping with these observations, elevated *IFNG* expression in ovarian cancer tumor tissue correlated with an improved clinical outcome in patients [43].

Our upstream regulator and functional annotations (Figs. 3b, c and 4c) yielded IFNγ and type I IFN as activated signaling pathways. We attribute this apparent ambiguity to the fact that type I and II target genes show substantial overlaps. Type I IFNs signal through their common receptor complex via JAK1/JAK2 to the heterotrimer ISGF3 (STAT1:STAT2:IRF9) and, to a lesser extent, through STAT1 homodimers, whereas IFNγ, the single type II IFN, uses only STAT1 homodimers phosphorylated by IFNγ receptor-associated JAK1/JAK2 [44]. Furthermore, STAT-independent pathways could be activated differentially by the different receptor complexes. Taken together, this explains the overlapping, but not identical, effects of the two types of IFNs. Interestingly, *JAK2* is among the signature B genes identified in this study (Fig. 3d, Additional file 2: Dataset S4) and might thus contribute to IFNγ-mediated effects. Taken together with our observation that, in contrast to *IFNG* (Fig. 6b), none of the type I IFN genes associated with a longer OS is expressed at significant levels by TAMs, TATs or tumor cells (Additional file 3: Figure S9) it is conceivable that upregulation of the IFN target genes of signature B is due to activated IFNγ signaling.

Collectively, these findings suggest that the increased expression of IFN target genes in cluster B TAMs results, at least in part, from an elevated level of IFNγ in the tumor microenvironment. Of note, a substantial fraction of the IFN signature genes upregulated in cluster B TAMs are also target genes of pro-inflammatory pathways (Additional file 3: Figure S3). This suggests that other cytokines present in ascites, notably TNFα [45], might contribute to the induction of these genes. This would be consistent with the prevailing opinion that pro-inflammatory macrophages inhibit tumor progression.

Since RNA-Seq measures mean transcript levels within a cell population, the fraction of TAMs expressing a given signature cannot be determined. It is therefore possible that elevated expression of IFN genes reflects the higher relative occurrence of a subpopulation of cells. These might be a newly recruited, CD163-negative, monocyte-like TAM subset similar to the macrophage fraction that is able to elicit inflammatory responses in
immune privileged reproductive organs [46]. This hypothesis is in agreement with the flow cytometry data in Fig. 2f, indicating that CD163+ and CD163− cells occur in both subgroup A and B, even though their ratio is clearly different in both subpopulations. Likewise, it is possible that a few TAM samples could not be fitted into either subgroup (Fig. 2a) due to the presence of similar fractions of functionally different subpopulations.

**Role of T cells**

Ascites contains substantial numbers of different types of T cells, in particular CD4+ and CD8+ cells [47, 48], known as important IFNγ producers under physiological conditions. A functional role of T cells in ovarian cancer is supported by many published observations strongly associating infiltrating T cells with a longer survival, with a high ratio of CD8+ versus regulatory T cells having a strong impact [47–49]. Consistent with these findings, transcriptome analyses defined distinct high-grade serous ovarian carcinoma subtypes, of which the immune reactive subtype was associated with the best prognosis [50]. Transcriptome profiling also identified several genes contributing to cytotoxic T lymphocyte recruitment as being differentially expressed in tumors with high versus low CD8+ T cell infiltration, including IRF1 [51–53], providing another link between T cells, IFNγ and a favorable clinical outcome. Furthermore, the analysis in Fig. 6a revealed a positive impact of IFNG expression on ovarian cancer OS. It is thus possible that IFNγ in the tumor microenvironment and the expression of IFN target genes in TAMs are indicators of the presence of activated, IFNγ secreting T and/or NK cells mediating anti-tumor immune responses.

Our RNA-Seq data support the conclusion that TATs are a major source of IFNγ in ascites (Fig. 6b). Since TATs showed a considerably higher level of IFNG expression compared to normal T cells, it is likely that the former are partially activated, at least in a subset of patients. This would be consistent with the observed clonal expansion of T cell subpopulations of unknown biological relevance in ovarian cancer ascites [54]. However, TATs apparently are not functional with respect to an anti-tumor response, as suggested by progression of the disease, presumably due the inhibitory effect of ascites on T cell activation [55]. In line with this conclusion other makers of an activated TH1, TH2, TH9 or TH17 response were only weakly upregulated in a subset of TATs relative to normal T cells (e.g., FASLG, GZMA, TNF), expressed at similar levels in both (e.g., CCR4, IL10, LAMP1/CD107A, LTA, PRF1) or not expressed at all (e.g., IL2, IL4, IL9, IL12B, IL13, IL17A) (Additional file 2: Dataset S1).

**Inflammatory signaling and IL-12 induction**

There is a large body of evidence to suggest that IFNγ and IL-12 are key determinants of a beneficial immune response in many cancers [56]. Physiologically, IL-12 is released by macrophages and other antigen-presenting cells in response to proinflammatory signals, including toll-like receptor ligands and IFNγ from T or NK cells. IL-12 in turn stimulates a cytotoxic response by inducing multiple immune stimulatory processes, including the differentiation of naive T cells into Th1 cells, the activation of CD8+ T cells and the maturation or activation of NK cells [57].

Multiple observations strongly support the hypothesis that IL-12, and probably its induction by IFNγ, are crucial determinants of ovarian cancer outcome. For example, IL-12 locally produced significantly delayed peritoneal disease development in a mouse model [32], engineered tumor-targeted T cells ectopically expressing a fused IL12A/IL12B cDNA have been reported to eradicate ovarian tumors in vivo [31] and a highly significant association was found between high IFNG and IL12B expression and a more favorable clinical outcome of advanced stage ovarian carcinoma [30].

In TAMs, the acquisition of a proinflammatory phenotype, including the secretion of IL-12, in response to proinflammatory signals is non-functional. In LPS-stimulated murine macrophages, IL12b induction is selectively dependent on the NFκB family member Rel [58] and on TLR signaling-induced chromatin remodeling which is independent of Rel [59]. Furthermore, IFNγ has been shown to enhance the synthesis of IL-12 by priming macrophages for LPS-mediated induction of the IL12B gene [60]. Finally, the nuclear accumulation of a NFκB p50 homodimer with presumed inhibitory function has been suggested for the acquisition of a TAM phenotype characterized by the defective production of IL-12 [33]. Intriguingly, IFNγ can prevent the inhibitory effect of ascites on the inducibility of IL12B in macrophages (Fig. 6d, e), consistent with a previous report that IFNγ was able to shift monocyte differentiation from TAM-like cells to pro-inflammatory macrophages [34]. It is currently unclear if, and if so how, TLR pathways, IFNγ triggered STAT signaling, chromatin remodeling and p50 accumulation functionally interact in the regulation/dysregulation of the IL12B gene in either normal macrophages or TAMs. Understand these connections will be crucial to be able to explore the potential of the IFNγ – IL-12 axis in stimulating cytotoxic immune responses and assess potential applications.

**Conclusions**

In the present study, we have address the question as to whether associated-derived TAMs from different patients with ovarian cancer represent a continuum of
overlapping transcriptomes or can be categorized into phenotypically distinct groups on the basis of their global gene expression patterns. The results of both principal component analysis (PCA) and coexpression analysis clearly demonstrated that the latter is the case, and lead to the definition of two highly distinct subgroups of patients differing in the expression of genes associated with cytokine signaling, immune regulation and extracellular matrix reorganization. One of the two subgroups identified (subgroup A) is associated with a high expression of protumorigenic, immunosuppressive and clinically unfavorable markers, including IL-6, IL-10, CD163 and PCOLCE2. By contrast, the second subgroup is characterized by the upregulation of genes linked to IFN signaling and associated with a longer survival. Expression of this IFN-related signature also showed a striking link to a longer survival, and IFNy abrogated the inhibitory effect of ovarian cancer ascites on the inducibility of IL-12 in cultured macrophages. As IL-12 is a key mediator of a cytotoxic immune response, this finding provides a possible explanation for the link of the IFN signaling-associated signature B to ovarian cancer survival.

Additional files

Additional file 1: Supplemental Table. Table S1: Patients data (RNA-Seq). (XLSX 49 kb)

Additional file 2: Supplemental Datasets S1-S10. Dataset S1: Complete RNA-Seq data. Dataset S2: EdgeR results. Dataset S3: Signature A expression data. Dataset S4: Signature B expression data. Dataset S5: Cluster I expression data. Dataset S6: Cluster II expression data. Dataset S7: Cluster III expression data. Dataset S8: Common cluster I / signature A genes. Dataset S9: Common cluster III / signature B genes. Dataset S10: PRECOG z-scores for signature A and B genes. (XLSX 6898 kb)

Additional file 3: Supplemental Figures S1-S8. Figure S1: Inverse association of PCOLCE2 expression with high-grade serous ovarian cancer survival (RFS). Figure S2: Hierarchical clustering of coexpressed high variance genes. Figure S3: Venn diagram showing the overlaps of the the upstream regulators genes sets identified in Fig. 3C. Figure S4: Subgroup-selective expression of signature genes. Figure S5: Association of signature A (top) and signature B (bottom) with ovarian cancer survival (OS). Figure S6: Association of the ECM remodeling-linked genes of signature A with high-grade serous ovarian cancer survival. Figure S7: Association of tumor-infiltrating host cells with high-grade serous ovarian cancer survival (OS). Figure S8: Expression of type I IFN genes in different cell types prevalent in ovarian cancer ascites. (PDF 1015 kb)

Abbreviations

GO: Gene ontology; IFN: Interferon; IL: Interleukin; LPS: Lipopolysaccharide; MDI: Monocyte-derived macrophage; OS: Overall survival; PCA: Principal component analysis; PCOLCE2: Procollagen C-endopeptidase enhancer 2; RFS: Relapse-free survival; RNA-Seq: RNA sequencing; TAM: Tumor-associated macrophage; TNF: Tumor necrosis factor α; TPM: Transcripts per million

Acknowledgements

We are grateful to T. Plaum and A. Allmeroth for expert technical assistance.

Funding

This research was supported by research grants from the Deutsche Forschungsgemeinschaft to SR (RE 1590/1-1 and RM (MU 601/17-1), by the Wilhelm-Sander-Stiftung to SR and UW and by UKGM Marburg to TA and UW.

Availability of data and materials

RNA-Seq were deposited at EBI ArrayExpress under accession numbers E-MTAB-5199 and E-MTAB-4162, respectively.

Authors’ contributions

TA and SL carried out RNA isolation, RT-qPCR analyses, RNA-Seq library construction and quality control experiments; AW performed all experiments with MDMs; SR prepared and characterized TAM samples and performed flow cytometry and ELISA analyses; FF and RM performed the bioinformatics analyses; AN and TS established NGS methodologies and acquired the RNA-Seq data; UW provided clinical samples and analyzed clinical data; TA, SR, SM and RM conceived the study and oversaw the project; RM wrote the paper. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

All patient samples were obtained according to the protocols approved by the ethics committee of Marburg University and in compliance with the Helsinki Declaration. All patients gave their written informed consent to provide the samples for this project.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Institute of Molecular Biology and Tumor Research (IMT), Center for Tumor Biology and Immunology (ZTI), Philipps University, Marburg, Germany. 2Genomics Core Facility, Center for Tumor Biology and Immunology (ZTI), Philipps University, Marburg, Germany. 3Clinic for Gynecology, Gynecological Oncology and Gynecological Endocrinology, Center for Tumor Biology and Immunology (ZTI), Philipps University, Marburg, Germany.

Received: 10 December 2016 Accepted: 15 March 2017

Published online: 21 March 2017

References

1. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1023–44.
2. Bowtell DD, Bohm S, Ahmed AA, Aspyria PJ, Bast Jr RC, Beral V, Berek JS, Birrer MJ, Bladgen S, Bookman MA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668–79.
3. Thibault B, Castells M, Delord JP, Coudenc B. Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev. 2014;33:17–39.
4. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.
5. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71–8.
6. Gabriovich DI, Osttrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253–68.
7. Williams CB, Yeh ES, Soloff AC. Tumor-associated macrophages: unifying accomplices in breast cancer malignancy. NPJ Breast Cancer. 2016;2. doi:10.1038/nbjca.2015.25.
8. Campbell MJ, Tondl LA, Bouchard EI, Breyer MD, King BM, et al. Estrogen receptor-positive breast cancer: clinical utility of pretreatment circulating tumor cell count. Breast Cancer Res Treat. 2012;133:679–83.
9. Tymowski A, Elmes M, Marzola V, Wachowicz K, Wasmier MH, Datta S, Muller-Holzner E, Fieg H, Bock G, van Rooijen N, et al. In situ proliferation contributes to ovarian cancer survival. (PDF 1015 kb)
to accumulation of tumor-associated macrophages in spontaneous mammary tumors. Eur J Immunol. 2014;44:2247–62.
10. Liu Y, Cao X. The origin and function of tumor-associated macrophages. Cell Mol Immunol. 2015;12:1–4.
11. Pucci F, Venneri MA, Bizzato D, Nonis A, Moi D, Sica A, Di Sitro C, Naldini L, De Palma M. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood “resident” monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood. 2009;114:901–14.
12. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:465–55.
13. Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, Pamer EG, Li MJ. The cellular and molecular origin of tumor-associated macrophages. Science. 2014;344:921–5.
14. Finkemagel F, Reinszt S, Lieber S, Adhikary T, Wortmann A, Hoffmann N, Bieringer T, Nist A, Stewte W, Jansen JM, et al. The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. Oncotarget. 2016;7:7339–52.
15. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49–61.
16. Reinszt S, Schummm T, Finkemagel F, Wortmann A, Jansen JM, Meissner W, Krause M, Schwerer AM, Wagner U, Muller-Brusselbach S, et al. Mixed-polarization phenotype of ascites-associated macrophages in ovarian human carcinoma: Correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2014;134:422–42.
17. Scambia G, Testa U, Benedetti Panici P, Poti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71:354–6.
18. Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 as levels in ovarian cancer patients. BMC Cancer. 2011;11:210.
19. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, Chang JS, Lai TC, Mizuno T, Suzuki N, Morii E, et al. Interleukin 6 receptor is an independent – wide validation of survival-associated biomarkers in ovarian cancer using microarray analysis. Int J Cancer. 2015;136:1622–8.
20. Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahody J, Denison U, Muller-Holzner E, Marx C. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer. 2000;82:1138–44.
21. Ziegert AG, Reimer D, Wolf D, Fiegl H, Convic N, Wiedemair E, Swi K, Muller-Holzner E, Marx C. Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer. Int J Cancer. 2005;116:2353–60.
22. Alberts DS, Hannigan EV, Liu PY, Jiang C, Wilczynski S, Copeland L, Markman M. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. Gynecol Oncol. 2006;100:133–8.
23. Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015;4:e994446.
24. Cohen CA, Shea AA, Heffron CL, Schmelz EM, Roberts PC. Interleukin-12 Immunomodulation Delays the Onset of Lethal Peritoneal Disease of Ovarian Cancer. J Interferon Cytokine Res. 2016;36:622–73.
25. Saccani A, Schioppa T, Porta C, Biasio SK, Nebuloni M, Vago L, Bottazzi B, Colombo MP, Mantovani A, Sica A. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006;66:11432–40.
26. Duluc D, Corsiaier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbel R, Jeannin P. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer. 2009;125:367–73.
27. Allavena P, Peccatori F, Maggioni D, Erroi A, Sironi M, Colombo N, Lissoni A, Galazka A, Meiers W, Mangioni C, et al. Intraperitoneal recombinant gamma interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res. 1990;50:7318–23.
28. Puaje-Laureaine E, Gustallia JP, Colomba D, Nevillier P, Francois E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol. 1996;14:343–50.
29. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:465–55.
30. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–40.
31. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khoury A, Haoing CD, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938–45.
32. Goyfob B, Lanncz A, Szallasi A. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19:197–208.
33. Isobe A, Sawada K, Kinose Y, Ohya-Hara C, Nakatsuka E, Makino H, Ogura T, Mizuno T, Suzuki N, Morii E, et al. Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer. PLoS ONE. 2015;10:e0118080.
34. Matte I, Lane D, Laplante C, Rancourt C, Piche A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res. 2012;2:566–80.
35. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Haoing CD, Dinh M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–7.
36. Kusuda T, Shigemasa K, Ahrhko F, Kulli T, Nagai N, Ohma K. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep. 2005;13:1153–8.
37. Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015;4:e994446.
38. Cohen CA, Shea AA, Heffron CL, Schmelz EM, Roberts PC. Interleukin-12 Immunomodulation Delays the Onset of Lethal Peritoneal Disease of Ovarian Cancer. J Interferon Cytokine Res. 2016;36:622–73.
39. Saccani A, Schioppa T, Porta C, Biasio SK, Nebuloni M, Vago L, Bottazzi B, Colombo MP, Mantovani A, Sica A. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006;66:11432–40.
40. Duluc D, Corsiaier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbel R, Jeannin P. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer. 2009;125:367–73.
41. Allavena P, Peccatori F, Maggioni D, Erroi A, Sironi M, Colombo N, Lissoni A, Galazka A, Meiers W, Mangioni C, et al. Intraperitoneal recombinant gamma interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res. 1990;50:7318–23.
42. Puaje-Laureaine E, Gustallia JP, Colomba D, Nevillier P, Francois E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol. 1996;14:343–50.
50. Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014;106.

51. Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, Sullivan EH, Hirsch MS, Matulonis UA, Liu J, Birrer MJ, et al. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res. 2008;14:7667–73.

52. Leffers N, Fehrmann RS, Goosen MJ, Schulze UR, Ten Hoor KA, Hollema H, Boezen HM, Daemen T, de Jong S, Nijman HW, et al. Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer. 2010;103:685–92.

53. Eng KH, Tsuji T. Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancers. PLoS ONE. 2014;9:e111586.

54. Jang M, Yew PY, Hasegawa K, Ikedo Y, Fujiwara K, Fleming GF, Nakamura Y, Park JH. Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. Oncoimmunology. 2015;4:e1030561.

55. Tran E, Nielsen JS, Wick DA, Ng AV, Johnson LD, Nesslinger NJ, McMurtrie E, Webb JR, Nelson BH. Polyclonal T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines. PLoS ONE. 2010;5:e15625.

56. Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16:131–44.

57. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, Cua DJ. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21:719–29.

58. Sanjabi S, Hoffmann A, Liou HC, Baltimore D, Smale ST. Selective requirement for c-Rel during IL-12 p40 gene induction in macrophages. Proc Natl Acad Sci U S A. 2000;97:12705–10.

59. Weinmann AS, Mitchell DM, Sanjabi S, Bradley MN, Hoffmann A, Liou HC, Smale ST. Nuclearosome remodeling at the IL-12 p40 promoter is a TLR-dependent, Rel-independent event. Nat. Immunol. 2001;2:51-57.

60. Ma X, Chow JM, Giri G, Carra G, Gerosa F, Wolf SF, Dzialo R, Trinchieri G. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocyctic cells. J Exp Med. 1996;183:147–57.